SER-155 is under clinical development by Seres Therapeutics and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SER-155’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SER-155 overview
SER-155 is under development for the treatment of antibiotic resistant bacterial infections including vancomycin-resistant Enterococcus faecium (VRE), carbapenem-resistant Klebsiella pneumoniae (CRE), post abx dysbiosis (prevention of transplant-related mortality in recipients of allogeneic hematopoietic stem cell transplant (HSCT) due to invasive infection (bacteremia) and graft versus host disease (GvHD) and to prevent mortality and morbidity due to gastrointestinal infections. The drug candidate is a multifunctional consortia of bacteria administered orally. It is an ecobiotic, developed based on human microbiome therapeutics technology.
Seres Therapeutics overview
Seres Therapeutics (Seres) is a commercial-stage company that develops novel microbiome therapeutics for serious diseases. The company’s drug candidate VOWST (SER-109) (fecal microbiota spores, live-brpk) treats clostridioides difficile infection (CDI). Its pipeline products include SER-155 an investigational, oral, fermented microbiome therapeutic designed that targets gastrointestinal infections, bacteremia and graft versus host disease (GvHD); SER-287 and SER-301 for ulcerative colitis. Seres works in collaboration with Memorial Sloan Kettering Cancer Center and Nestle Health Science S.A. The company operates through its subsidiaries in the US, the UK and the Netherlands. Seres is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of SER-155’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
